TABLE 1.
Demographic and clinical characteristics
| Patient characteristics | ICI + SBRT (n = 16) | ICI (n = 5) | |
|---|---|---|---|
| Gender (n) | Female | 9 | 3 |
| Male | 7 | 2 | |
| Race (n) | Caucasian | 13 | 4 |
| African American | 1 | 0 | |
| Other | 2 | 1 | |
| Age (years) | Mean; Range | 48.5; 22–81 | 56 ± 11; 26–67 |
| KPS (n) | ≥70 | 14 | 3 |
| <70 | 2 | 2 | |
| Initial resection extent (n) | Gross Total Resection | 9 | 1 |
| Subtotal Resection | 4 | 3 | |
| Biopsy | 3 | 1 | |
| WHO tumor grade (n) | 4 | 10 | 2 |
| 3 | 6 | 3 | |
| MGMT methylation status (n) | Methylated | 4 | 1 |
| Unmethylated | 12 | 4 | |
| IDH mutation status (n) | Mutated | 3 | 0 |
| Wild type | 0 | 5 | |
| TERT promotor mutation (n) | Mutated | 10 | 2 |
| Wild type | 0 | 3 | |
| Adjuvant TMZ + radiation (n) | Yes | 12 | 4 |
| No | 4 | 1 | |
| Lines of therapy (including TMZ + radiation) | Mean; Range | 4.5 ± 1.7; 2–8 | 4.4 ± 1.6; 3–7 |
Abbreviations: IDH, isocitrate dehydrogenase; KPS, Karnofsky Performance Status; MGMT, O6‐Methylguanine‐DNA Methyltransferase; TERT, telomerase reverse transcriptase gene promoter; TMZ, temozolomide; WHO, World Health Organization.